Skip to main
OPK
OPK logo

OPKO Health (OPK) Stock Forecast & Price Target

OPKO Health (OPK) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 45%
Buy 36%
Hold 18%
Sell 0%
Strong Sell 0%

Bulls say

OPKO Health's strategic focus on its drug development capabilities is expected to enhance its financial health, particularly by improving its balance sheet following recent transactions. The company reported a cash position that has been strengthened and achieved revenue growth of 0.9% year-over-year in 4Q24, with total revenue reaching $183.6 million, which exceeded projections. Additionally, the implementation of cost-reduction measures at BioReference and an anticipated path towards profitability by 2025 further supports a positive outlook for OPKO Health's financial performance.

Bears say

OPKO Health Inc. reported a significant decline in key revenue streams, with Diagnostics services revenue dropping 17% year-over-year to $103.1 million, driven by reduced clinical test volumes following the sale of certain BioReference assets. For the full year 2024, total revenue decreased by 17% to $713.1 million, while pharmaceutical products revenue fell by 13% to $37.4 million, largely due to adverse foreign currency exchange fluctuations. The company's outlook is further clouded by multiple risks, including underperformance in diagnostics services growth, challenges in securing regulatory approval for new pharmaceuticals, and considerable volatility in foreign exchange rates.

OPKO Health (OPK) has been analyzed by 11 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 36% recommend Buy, 18% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of OPKO Health and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About OPKO Health (OPK) Forecast

Analysts have given OPKO Health (OPK) a Buy based on their latest research and market trends.

According to 11 analysts, OPKO Health (OPK) has a Buy consensus rating as of Jul 23, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.07, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.07, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

OPKO Health (OPK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.